Teva Pharmaceutical Industries Ltd (TEVA) Stock Price & Analysis
Teva Pharmaceutical Industries Ltd (TEVA) rose 3.58% to USD 34.45 as of June 9, 2026 at 23:56 UTC, according to Nexqual real-time market data.
TEVA last closed at USD 33.26; the session ranged USD 32.91–34.47 on volume of 4,086,754 shares. Market capitalization is $40.11B, with a 52-week range of USD 14.99–37.35 (NYQ). Source: Nexqual, June 9, 2026 at 23:56 UTC.
Key Statistics (as of June 9, 2026 at 23:56 UTC)
| Price | USD 34.45 |
|---|---|
| Change | ▲ 3.58% (up) |
| Previous Close | USD 33.26 |
| Open | USD 33.48 |
| Day Range | USD 32.91 – 34.47 |
| 52-Week Range | USD 14.99 – 37.35 |
| Volume | 4,086,754 shares |
| Market Cap | $40.11B |
| Exchange | NYQ |
Technical Analysis (TEVA)
Nexqual's technical model rates TEVA "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 23:56 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.4 (neutral) |
| vs SMA50 | Above (USD 33.13) |
| MACD | 0.08 (positive) |
Analyst Ratings (TEVA)
Wall Street analysts rate TEVA "Strong Buy" based on 11 analysts, with a mean price target of USD 41.27 (range USD 33–50), per Nexqual as of June 9, 2026 at 23:56 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 41.27 |
| High Target | USD 50 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (TEVA)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.55 |
| Revenue Estimate | $4.07B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.53 vs est 0.46 ▲ beat |
| 2025-12-31 | USD 0.96 vs est 0.64 ▲ beat |
| 2025-09-30 | USD 0.78 vs est 0.67 ▲ beat |
| 2025-06-30 | USD 0.66 vs est 0.62 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financials & Fundamentals (TEVA)
| Total Revenue | $17.35B |
|---|---|
| Revenue Growth (YoY) | +2.30% |
| Gross Margin | +52.06% |
| Operating Margin | +19.16% |
| Profit Margin | +9.02% |
| ROE | +21.60% |
| Debt / Equity | 205.6 |
| Current Ratio | 1.01 |
| Total Cash | $3.74B |
| Total Debt | $16.92B |
| Free Cash Flow | $2.61B |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Financial Health Score (TEVA)
Nexqual rates Teva Pharmaceutical Industries Ltd's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:56 UTC.
| Growth | Mixed — Revenue +4.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 19% |
| Balance Sheet | Weak — $3.74B cash vs $16.9B debt |
| Cash Flow | Strong — FCF $2.61B, 15% margin |
| Efficiency | Strong — ROE 22%, ROA 6.4% |
Ownership (TEVA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +62.20% |
| Shares Outstanding | 1.16B |
| Float | 1.08B |
| Short % of Float | +2.92% |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
Leadership (TEVA)
Teva Pharmaceutical Industries Ltd is led by Richard D. Francis (age 57), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:56 UTC.
| President, CEO & Director | Richard D. Francis (age 57) |
|---|---|
| Executive VP & CFO | Eliyahu Sharon Kalif (age 51) |
| Executive Vice President of Business Development | Evan Lippman (age 55) |
| Executive Vice President of Global Operations | Matthew Shields (age 50) |
| Senior Vice President of Investor Relations & Competitive Intelligence | Christopher J. Stevo |
Major Backers & Investors (TEVA)
Notable institutional backers of Teva Pharmaceutical Industries Ltd include Harel Insurance Investments & Financial Services Ltd., Phoenix Financial Ltd., WCM Investment Management, LLC, according to Nexqual as of June 9, 2026 at 23:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harel Insurance Investments & Financial Services Ltd. | 3.95% |
| Phoenix Financial Ltd. | 3.67% |
| WCM Investment Management, LLC | 3.51% |
| Menora Mivtachim Holdings Ltd. | 3.4% |
| Clal Insurance Enterprises Holdings Ltd | 3.3% |
| Migdal Insurance & Financial Holdings Ltd. | 3.25% |
| FMR, LLC | 2.84% |
| Lingotto Investment Management LLP | 2.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.93% |
| State Street | 1.53% |
Source: Nexqual, June 9, 2026 at 23:56 UTC.
From Teva Pharmaceutical Industries Ltd's Latest SEC 10-K Filing (filed 2026-02-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products.
- If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, our results of operations, financial condition and cash flows could suffer.
- Any manipulation, theft, loss and/or fraudulent use of customer, employee or proprietary data as a result of a cyber-attack targeting us or one of our third-party service providers could subject us to significant litigation, liability and costs, as well as adversely impact our reputation with customers and regulators.
- We may not be successful in seeking or consummating appropriate opportunities to enable us to execute on our business strategy.
Partnerships
- In 2016, we paid a monetary fine for FCPA violations and entered into a three-year deferred prosecution agreement with the DOJ, which included retaining an independent compliance monitor.
- In addition, we, or the partners with which we may enter into licensing or other collaboration agreements, may not be able to perform effectively under such agreements, impairing our ability to monetize opportunities related to them.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GILD | Gilead Sciences, Inc. | USD 125.5 | ▼ 2.83% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| BIIB | Biogen Inc. | USD 199.1 | ▲ 1.92% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
| AMGN | Amgen Inc. | USD 344.57 | ▼ 1.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:56 UTC. This page is informational and not investment advice.